Skip to content

Study · Randomized controlled trial · 1992

3 results

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

Overgaard K, Hansen MA, Jensen SB, Christiansen C

BMJ (Clinical research ed.)1 Sept 1992Cited by 228 (Europe PMC)

PMID1393035 (opens in a new tab)PMCIDPMC1883290 (opens in a new tab)DOI10.1136/bmj.305.6853.556 (opens in a new tab)PepBankPUB-01393035
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In elderly women with osteoporosis, spinal bone mineral content showed a positive average change of 3% (95% CI 1.8% to 4.2%) with salcatonin 200 IU versus 1% (95% CI -0.1% to 1.5%) with calcium alone (placebo).

    In plain wordsIn elderly women with osteoporosis, spinal bone mineral content rose 3% with salcatonin 200 IU and 1% with placebo plus calcium.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseSpinal bone mineral content
    Study

    n: not reported in source

    Comparator
    Placebo (calcium alone)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Spinal bone mineral content change
    3%
    salcatonin 200 IU group
    Spinal bone mineral content change, 95% CI
    1.8 to 4.2%
    salcatonin 200 IU group
    Spinal bone mineral content change
    1%
    placebo (calcium) group
    Spinal bone mineral content change, 95% CI
    −0.1 to 1.5%
    placebo (calcium) group

    Source sentences

    Summary
    The average changes in bone mineral content of the spine showed positive outcomes of 1% (95% confidence interval -0.1% to 1.5%) in the group treated with calcium (placebo) and 3% (1.8% to 4.2%) in the group treated with salcatonin 200 IU.
    2 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    208 healthy women aged 68-72 years who had a bone mineral content of the distal forearm on average 30% below the mean value for healthy premenopausal women.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In elderly women with osteoporosis, spinal bone mineral content increased by 1.0%/100 IU of salcatonin (interval 0.2% to 1.7%, p = 0.008).

    In plain wordsIn elderly women with osteoporosis, spinal bone mineral content increased with the salcatonin dose.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseSpinal bone mineral content dose response
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 IU, 100 IU or 200 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Spinal bone mineral content dose response
    1 %/100 IU
    salcatonin dose-response over 2 years, p = 0.008
    Spinal bone mineral content dose response, interval
    0.2 to 1.7 %/100 IU
    interval

    Source sentences

    Summary
    There was a significant dose related response to salcatonin, manifested by an increase of 1.0%/100 IU (0.2% to 1.7%, p = 0.008).
    2 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    208 healthy women aged 68-72 years who had a bone mineral content of the distal forearm on average 30% below the mean value for healthy premenopausal women.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In elderly women with osteoporosis, salcatonin reduced new fractures versus no salcatonin (relative risk 0.23, interval 0.07 to 0.77).

    In plain wordsIn elderly women with osteoporosis, salcatonin reduced new fractures compared with no salcatonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseNew fractures
    Study

    n: not reported in source

    Comparator
    No salcatonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 IU, 100 IU or 200 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Relative risk of new fractures
    0.23 ratio
    salcatonin-treated versus non-salcatonin treated women
    Relative risk of new fractures, interval
    0.07 to 0.77 ratio
    interval

    Source sentences

    Summary
    The rate of patients with new fractures was reduced significantly in the women treated with salcatonin to about one third of that in the non-salcatonin treated women (relative risk 0.23 (0.07 to 0.77)).
    2 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    208 healthy women aged 68-72 years who had a bone mineral content of the distal forearm on average 30% below the mean value for healthy premenopausal women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.